List of Excipients in Branded Drug ATRALIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	BENZYL ALCOHOL
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	BUTYLATED HYDROXYTOLUENE
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	BUTYLPARABEN
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	CARBOMER HOMOPOLYMER TYPE C
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	ETHYLPARABEN
Bausch Health US LLC	ATRALIN	tretinoin	13548-070	GLYCERIN

Atralin Excipient Strategy and Commercial Opportunities for Tretinoin 0.05% Gel

Last updated: August 27, 2026

Atralin is a prescription topical gel containing tretinoin 0.05% for acne vulgaris. Its commercial differentiation is primarily vehicle-based rather than active-ingredient-based. The formulation uses a water-based carbomer gel with glycerin, propylene glycol, tromethamine, methylparaben, and edetate disodium. The main opportunities are generic-equivalent supply, improved tolerability, preservative-free delivery, packaging innovation, and differentiated 505(b)(2) products. Tretinoin is a small molecule, so biosimilar competition does not apply.

What is Atralin and what FDA product does it contain?

Atralin is a prescription topical gel containing 0.05% tretinoin, equivalent to 0.5 mg/g. The product is indicated for the topical treatment of acne vulgaris in patients aged 10 years and older. The FDA-approved dosage is a thin layer applied once daily to affected areas.[1]

Attribute	Atralin
Active ingredient	Tretinoin
Strength	0.05%
Dosage form	Topical gel
Route	Cutaneous
FDA application	NDA 021753
Therapeutic category	Topical retinoid; acne treatment
Product type	Small-molecule drug
Regulatory pathway	Original NDA; generic products may use ANDA
Biosimilar exposure	None
Primary differentiation	Vehicle tolerability, spreadability, cosmetic acceptability, packaging

Atralin is distinct from tretinoin creams, microsphere gels, lotions, and other branded formulations. FDA approval of a generic tretinoin product depends on pharmaceutical equivalence and bioequivalence or an applicable topical-product equivalence framework, not merely on matching the active ingredient concentration.

What excipients are used in Atralin gel?

The Atralin label identifies the following inactive ingredients: purified water, carbomer 974P, edetate disodium, glycerin, methylparaben, propylene glycol, and tromethamine.[1]

Excipient	Primary formulation function	Commercial relevance
Purified water	Continuous aqueous phase	Controls viscosity, evaporation, and feel
Carbomer 974P	Gelling and rheology modifier	Determines yield value, suspension, and application profile
Glycerin	Humectant and skin-conditioning agent	Supports moisturization and reduces dry-feel perception
Propylene glycol	Humectant, solvent, and penetration-supporting excipient	Affects drug solubilization and irritation potential
Tromethamine	pH adjuster and neutralizing agent	Controls carbomer viscosity and tretinoin stability environment
Methylparaben	Preservative	Supports microbiological protection in a water-containing product
Edetate disodium	Chelating agent	Binds metal ions and can improve preservative and chemical stability

The formulation is a conventional aqueous carbomer gel. Carbomer neutralization with tromethamine creates the gel structure. Glycerin and propylene glycol improve wetting and skin feel, while the preservative and chelator address microbial and oxidative risks associated with an aqueous topical product.

How does Atralin’s excipient strategy affect product performance?

The excipient system influences four commercially important attributes: irritation, adherence, dose uniformity, and consumer acceptability.

Rheology and application

Carbomer 974P controls viscosity and yield stress. A gel that is too thin may run, spread beyond the intended area, or deliver inconsistent dosing. A gel that is too stiff may pill, leave residue, or discourage daily use.

For an ANDA product, a supplier must control:

• Carbomer grade and substitution characteristics
• Polymer hydration time
• Neutralization endpoint
• Mixing shear
• pH
• Viscosity at multiple shear rates
• Fill weight and content uniformity

Small changes in polymer level or neutralization can change the product’s application behavior without changing the labeled active concentration.

Skin feel and tolerability

Tretinoin commonly causes dryness, erythema, peeling, burning, and stinging during treatment initiation. Glycerin and propylene glycol can improve hydration and solubilization, but propylene glycol may increase irritation in sensitive users. A commercial formulation strategy must balance solvent capacity against tolerability.

The most valuable performance targets are:

1. Low tack after application.
2. Minimal pilling under sunscreen or cosmetics.
3. Rapid absorption without excessive residue.
4. Reduced sting and dryness.
5. Consistent delivery across the labeled shelf life.

Chemical and physical stability

Tretinoin is sensitive to light and can undergo degradation under unfavorable conditions. The vehicle, pH, oxygen exposure, container-closure system, and filling process all affect stability. Packaging is therefore part of the formulation strategy.

Relevant controls include:

• Protection from light during manufacturing and storage
• Low headspace oxygen where practicable
• Compatibility between gel and tube or pump components
• Assay and degradation-product limits
• Preservative effectiveness
• Freeze-thaw and accelerated-stability performance

Microbiological protection

Atralin is a multidose aqueous product. Methylparaben supplies preservative activity, while edetate disodium can improve preservative performance by reducing the effect of metal-ion-mediated microbial resistance and degradation pathways.

A preservative-free version would require a different microbiological control strategy, such as:

• Airless packaging
• Unit-dose delivery
• Reduced product-contact exposure
• Validated microbial limits
• A demonstrated preservative-free multidose design

A preservative-free claim cannot be supported by removing methylparaben alone. The complete container-closure and manufacturing system would need to demonstrate acceptable microbiological control.

What commercial opportunities exist for Atralin excipients?

Generic-equivalent Atralin

The most direct opportunity is a therapeutically equivalent tretinoin 0.05% gel. Generic manufacturers can compete through:

• Lower cost of goods
• Reliable supply of carbomer and preservative systems
• Efficient tube filling
• Private-label dermatology distribution
• Pharmacy benefit-manager contracting
• Dermatology-clinic and telehealth channels

The main barrier is not the cost of tretinoin. It is reproducing the critical quality attributes of the reference gel while controlling particle size, viscosity, assay, degradation products, microbial quality, and packaging compatibility.

Improved-tolerability gel

A differentiated topical retinoid can target the principal weakness of conventional tretinoin: treatment-related irritation. Potential strategies include:

• Lower-irritancy solvent systems
• Alternative humectant combinations
• Barrier-supportive excipients
• Reduced residual tack
• Controlled-release polymer networks
• Encapsulation or microdispersion
• A lower-irritancy preservative system

These changes may support a 505(b)(2) application if the product relies on published literature or the reference product while introducing a clinically meaningful formulation difference.[2]

Preservative-free and sensitive-skin formulations

Preservative-free dermatology products are commercially attractive for patients who experience irritation or who prefer simplified ingredient lists. Tretinoin presents a technical challenge because the product is aqueous and typically sold in a multidose container.

A viable opportunity is an airless pump or unit-dose system that removes methylparaben while maintaining:

• Dose reproducibility
• Protection from air and light
• Microbial control
• Acceptable stability
• Consumer convenience

This product would require a clear clinical and regulatory rationale. A preservative-free claim alone may not justify premium pricing unless it improves tolerability, adherence, or patient preference.

Cosmetically elegant delivery

Tretinoin products compete with nonprescription retinol and retinaldehyde products in the broader anti-aging market. A prescription-strength tretinoin gel can gain commercial share through an improved sensory profile:

• Fast rub-in
• No visible residue
• Low odor
• Minimal flaking
• Compatibility with makeup
• Non-greasy finish
• Convenient pump delivery

Cosmetic elegance can improve refill persistence, an important commercial metric in chronic acne and photoaging treatment.

Combination products

Potential combination opportunities include tretinoin with:

• Benzoyl peroxide
• Clindamycin
• Niacinamide
• Azelaic acid
• Barrier-supportive ingredients
• Antimicrobial or anti-inflammatory agents

Combination products raise compatibility and regulatory complexity. Benzoyl peroxide is particularly relevant because oxidative conditions can affect tretinoin stability. A combined product would require robust degradation, packaging, and clinical-performance data.

What patents protect Atralin and how strong is its patent estate?

Atralin’s core active ingredient, tretinoin, is an old and widely used molecule. The commercial value of the product therefore depends more on formulation, delivery, manufacturing, and branding than on composition-of-matter protection.

Orange Book status

The FDA Orange Book is the controlling source for current listed patents and exclusivity associated with NDA 021753.[3] Atralin’s original FDA approval dates to 2006, and any original regulatory exclusivity has expired. Current competitive risk is therefore primarily generic substitution rather than loss of remaining new-drug exclusivity.

For diligence purposes, the relevant patent categories are:

Patent category	Relevance to Atralin
Tretinoin composition-of-matter patent	No meaningful current barrier
Atralin formulation patent	Could affect a specific gel composition if unexpired and listed
Method-of-use patent	Could cover an acne population, dosing method, or treatment regimen
Packaging patent	Could protect a pump, tube, or light-protection system
Manufacturing patent	Could restrict a process but usually does not prevent all generic entry
Trade secret	May protect process parameters, but not normally block an equivalent product

A generic applicant can challenge an Orange Book-listed patent through a Paragraph IV certification. The applicant must certify that the patent is invalid, unenforceable, or will not be infringed.[4] A patent infringement action filed within the statutory period can trigger a 30-month stay of FDA approval, subject to statutory exceptions and litigation outcomes.

How strong is the remaining patent estate?

The estate is structurally weaker than that of a newer branded dermatology product because:

• Tretinoin itself is no longer a meaningful exclusivity asset.
• The dosage form is technically conventional.
• Multiple tretinoin topical products establish broad prior art.
• Generic manufacturers can use different excipient systems if they satisfy FDA equivalence requirements.
• Formulation claims must be narrow enough to distinguish prior art but broad enough to cover commercial alternatives.

The strongest protectable areas would be a demonstrably superior delivery system, a specific stability-enhancing combination, a novel low-irritancy vehicle, or a clinically validated treatment method.

What is the FDA regulatory pathway for competing Atralin products?

ANDA pathway

A generic tretinoin 0.05% gel may use an ANDA if it can demonstrate the required equivalence to the reference-listed drug. The applicant generally must address:

• Same active ingredient
• Same strength
• Same dosage form
• Same route of administration
• Pharmaceutical equivalence
• Appropriate bioequivalence or product-performance evidence
• Labeling requirements
• Manufacturing controls
• Container-closure compatibility

Inactive ingredients do not necessarily have to be identical. They must be acceptable for the route and dosage form, and the finished product must meet FDA requirements.

505(b)(2) pathway

A reformulated product may use a 505(b)(2) application when it differs materially from the reference product and cannot rely entirely on the ANDA framework. Potential differentiators include:

• New delivery technology
• Different dosing frequency
• A new indication
• Improved tolerability
• New container-closure system
• Combination with another active ingredient

The 505(b)(2) route can support premium pricing but requires a stronger clinical and regulatory package than a standard generic.

Which companies are challenging or competing with Atralin?

The competitive field includes generic tretinoin suppliers and branded topical retinoid products. Key competing products include:

Product	Active ingredient	Dosage form	Competitive position
Generic tretinoin	Tretinoin	Cream, gel, lotion	Price competition
Retin-A	Tretinoin	Cream, gel, microsphere gel	Established brand
Retin-A Micro	Tretinoin	Microsphere gel	Delivery and tolerability differentiation
Altreno	Tretinoin	Lotion	Lotion vehicle and cosmetic acceptability
Tazorac and generics	Tazarotene	Cream, gel, foam, lotion	Alternative topical retinoid
Differin and generic adapalene	Adapalene	Gel, cream, lotion	Acne-focused retinoid competitor
Aklief	Trifarotene	Cream	Newer retinoid positioning
Topical retinol products	Retinol	Cosmetic formulations	OTC anti-aging competition

The principal generic threat is from suppliers able to manufacture a stable, cosmetically acceptable tretinoin gel at scale. The principal branded threat is from products that reduce irritation or offer more attractive application characteristics.

What generic launch risks exist for Atralin?

Generic launch risk is high because the product has an old active ingredient, an established therapeutic class, and no biosimilar barrier. The primary launch scenarios are:

Scenario 1: Standard generic gel

This is the most likely competitive model. The product matches the reference strength and dosage form while using the same or functionally similar excipients. Price erosion and pharmacy substitution would be expected.

Scenario 2: Multiple generic entrants

Several approved products could compress reimbursement and wholesale acquisition pricing. Tretinoin products already compete across multiple dosage forms, making channel access and supply reliability important.

Scenario 3: Premium reformulated product

A low-irritancy or preservative-free product could avoid direct price competition if it earns differentiated coverage or strong dermatology adoption. This path would require clinical evidence and a defensible delivery or method-of-use position.

Scenario 4: OTC substitution

Consumers may substitute retinol or adapalene products for some acne or anti-aging use cases. OTC alternatives typically have lower tretinoin-like potency but compete on access, tolerability, and price.

What manufacturing and IP barriers affect Atralin opportunities?

The key manufacturing barriers are process-control barriers rather than raw-material scarcity.

Critical manufacturing variables include:

• Carbomer dispersion without agglomeration
• Complete polymer hydration
• Controlled neutralization
• Uniform tretinoin distribution
• Protection from light and oxygen
• Low-shear filling that preserves gel structure
• Tube or pump compatibility
• Preservative effectiveness
• Stability under transport conditions

A supplier with validated topical-gel manufacturing, reliable carbomer sourcing, and dermatology-focused packaging can compete more effectively than a supplier that only has access to tretinoin API.

Geographic coverage depends on separate regulatory approvals. FDA approval supports U.S. marketing only. European, Canadian, Australian, and other regulatory systems may require different reference products, local labeling, stability data, and manufacturing documentation. A global strategy should avoid assuming that U.S. equivalence automatically transfers to other jurisdictions.

How does Atralin compare with newer tretinoin formulations?

Atralin uses a conventional aqueous gel architecture. Newer products often compete through delivery and tolerability.

Attribute	Atralin-type gel	Microsphere gel	Lotion	Cream
Primary advantage	Familiar gel platform	Controlled release and lower irritation potential	Cosmetic elegance	Emollience and moisturization
Main risk	Dryness and stinging	Higher manufacturing complexity	Stability and preservative design	Greasiness or comedogenic perception
Generic complexity	Moderate	High	Moderate to high	Moderate
Premium opportunity	Limited without reformulation	Stronger	Stronger	Moderate
Packaging sensitivity	High	High	High	Moderate

A commercial developer should treat excipients, packaging, and sensory performance as a unified product system. Changing the gel polymer without reassessing tube extraction, dosing, stability, and patient experience can create avoidable regulatory and commercial problems.

Key Takeaways

• Atralin is a tretinoin 0.05% aqueous gel approved for acne vulgaris.
• Its excipient system is built around carbomer 974P, glycerin, propylene glycol, tromethamine, methylparaben, and edetate disodium.
• The formulation’s main value lies in rheology, skin feel, stability, and preservative control.
• Generic-equivalent entry is commercially feasible and presents high substitution risk.
• Biosimilar risk does not apply because tretinoin is a small molecule.
• The strongest commercial opportunities are low-irritancy, preservative-free, cosmetically elegant, and controlled-delivery formulations.
• A standard generic would generally compete on cost and supply reliability.
• A differentiated product would more likely require a 505(b)(2) strategy and clinical support.
• Manufacturing know-how and packaging compatibility are more important barriers than access to tretinoin API.
• Current Orange Book listings and patent status should be evaluated against the FDA’s live records for NDA 021753 before a launch or litigation decision.

FAQs About Atralin Excipient and Commercial Strategy

Is Atralin a gel or a cream?

Atralin is a topical gel containing tretinoin 0.05%. Its aqueous carbomer system differs from tretinoin creams and lotions.

Does Atralin contain propylene glycol?

Yes. Propylene glycol is listed as an inactive ingredient and functions as a solvent, humectant, and penetration-supporting excipient.[1]

Can a generic Atralin use different excipients?

Yes, subject to FDA requirements for inactive-ingredient acceptability, equivalence, product quality, and regulatory approval. The finished product must demonstrate the required performance against the reference product.

Is there a preservative-free Atralin opportunity?

Yes. A preservative-free version could use airless, unit-dose, or other protective packaging, but the complete system would need to demonstrate microbiological control, stability, and dose performance.

What is the best premium strategy for a new tretinoin product?

A low-irritancy, cosmetically elegant formulation with strong adherence data offers a more defensible premium strategy than a simple excipient substitution.

References

1. U.S. Food and Drug Administration. (2006). Atralin (tretinoin) gel, 0.05% prescribing information. NDA 021753.
2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Paragraph IV certifications and patent litigation under the Hatch-Waxman Act.